Bio-Rad Laboratories, Inc. BIO | NYSE

$247.52 $6.20 | 2.57%

Next Earnings: Jul 30, 2025

Company Overview:

Market Cap: $6.73B
PE Ratio: -3.23
52-Week Range: $211.43 - $387.99

10 Year BIO Performance Metrics:

Total Return (with DRIP): 68.1% (5.33% CAGR)
Total Return (no DRIP): 68.1% (5.33% CAGR)
Share Price: 68.1% (5.33% CAGR)
BIO Total Return
1Y 2Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Monthly
$35/mo
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 20% OFF
$336/yr
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial

BIO Earnings, Revenue, Cash & Debt, Shares Outstaning:

BIO - Revenue
7-Day FREE Trial Get Full Access Now!
BIO Revenue CAGR:1Y: -4.16%2Y: -7.00%5Y: 0.48%10Y: 2.16%
BIO - Earnings Per Share (EPS)
7-Day FREE Trial Get Full Access Now!
BIO EPS CAGR:1Y: -82.97%2Y: -0.65%5Y: -36.80%10Y: 14.14%
BIO - Net Income
7-Day FREE Trial Get Full Access Now!
BIO Net Income CAGR:1Y: -99.98%2Y: -96.95%5Y: -84.37%10Y: -43.04%
BIO - EBITDA
7-Day FREE Trial Get Full Access Now!
BIO EBITDA CAGR:1Y: -75.78%2Y: -5.00%5Y: 3.72%10Y: 7.01%
BIO - Free Cash Flow
7-Day FREE Trial Get Full Access Now!
BIO Free Cash Flow CAGR:1Y: 229.32%2Y: 23.72%5Y: 18.36%10Y: 56.86%
BIO - Free Cash Flow / Share
7-Day FREE Trial Get Full Access Now!
BIO Free Cash Flow / Share CAGR:1Y: 236.12%2Y: 27.33%5Y: 19.94%10Y: 57.49%
BIO - Operating Income
7-Day FREE Trial Get Full Access Now!
BIO Operating Income CAGR:1Y: -54.43%2Y: -54.07%5Y: -20.45%10Y: -3.64%
BIO - Gross Profit
7-Day FREE Trial Get Full Access Now!
BIO Gross Profit CAGR:1Y: -6.27%2Y: -8.11%5Y: -0.73%10Y: 1.26%
BIO - Shares Outstanding
7-Day FREE Trial Get Full Access Now!
BIO Shares Outstanding CAGR:1Y: -2.04%2Y: -3.06%5Y: -1.53%10Y: -0.47%
BIO - Share Buybacks
7-Day FREE Trial Get Full Access Now!
BIO Share Buybacks CAGR:1Y: -100.00%2Y: -100.00%5Y: -100.00%10Y: 0.00%
BIO - Stock-Based Comp
7-Day FREE Trial Get Full Access Now!
BIO Stock-Based Comp CAGR:1Y: -100.00%2Y: -100.00%5Y: -100.00%10Y: -100.00%
BIO - Expenses
7-Day FREE Trial Get Full Access Now!
BIO Expenses CAGR:1Y: -14.38%2Y: -1.87%5Y: 9.66%10Y: 1.94%
BIO - Revenue vs Net Income
7-Day FREE Trial Get Full Access Now!
BIO - EPS vs FCF / Share
7-Day FREE Trial Get Full Access Now!
BIO - EPS vs PE Ratio
7-Day FREE Trial Get Full Access Now!
BIO - FCF vs FCF / Share
7-Day FREE Trial Get Full Access Now!
BIO - FCF vs Stock Based Comp
7-Day FREE Trial Get Full Access Now!
BIO - Cash & Debt
7-Day FREE Trial Get Full Access Now!
BIO - Revenue by Segment
7-Day FREE Trial Get Full Access Now!
BIO Revenue CAGR:1Y: -4.16%2Y: -7.00%5Y: 0.48%10Y: 2.16%
BIO - Revenue by Region
7-Day FREE Trial Get Full Access Now!
BIO Revenue CAGR:1Y: -4.16%2Y: -7.00%5Y: 0.48%10Y: 2.16%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

BIO - REVENUE: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
BIO Actual Revenue CAGR:1Y: -4.16%2Y: -7.00%5Y: 0.48%10Y: 2.16%
BIO - EPS: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
BIO Actual EPS CAGR:1Y: -82.97%2Y: -0.65%5Y: -36.80%10Y: 14.14%
BIO - NET INCOME: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
BIO Actual Net Income CAGR:1Y: -99.98%2Y: -96.95%5Y: -84.37%10Y: -43.04%
BIO - EBITDA: Actual + Estimates
7-Day FREE Trial Get Full Access Now!
BIO Actual EBITDA CAGR:1Y: -75.78%2Y: -5.00%5Y: 3.72%10Y: 7.01%

Ratios, Profit Margins & Return on Capital:

BIO - Net Profit Margin
7-Day FREE Trial Get Full Access Now!
BIO Net Profit Margin CAGR:1Y: -99.98%2Y: -96.87%5Y: -84.72%10Y: -44.75%
BIO - Gross Profit Margin
7-Day FREE Trial Get Full Access Now!
BIO Gross Profit Margin CAGR:1Y: -2.21%2Y: -1.20%5Y: -1.20%10Y: -0.89%
BIO - Price to Earnings
7-Day FREE Trial Get Full Access Now!
BIO - Price To Sales Ratio
7-Day FREE Trial Get Full Access Now!
BIO - Return on Capital Employed
7-Day FREE Trial Get Full Access Now!
BIO - Return on Invested Capital
7-Day FREE Trial Get Full Access Now!

Compare stocks side-by-side
 

Projected Future Returns & Dividends for BIO

Based on past 10-year performance, here are BIO growth metrics:

Share price CAGR of +5.33%
Dividend CAGR of +0%

Using BIO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

BIO (DRIP)BIO - No DRIP
Current Price$252.09$252.09
Start Shares39.6739.67
Start Value$10,000$10,000
  
After 10 years:
Final Share Count39.6739.67
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$402.35$252.09
Total Dividends$0$0
Final Value$15,961$10,000

Estimated Future Value + Dividends - BIO

NOTE: Above numbers are our estimate based on BIO's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Monthly
$35/mo
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 20% OFF
$336/yr
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial

Company Info

Bio-Rad Laboratories, Inc. (BIO) had its IPO on 1980-02-27, and is trader on NYSE stock exchange.

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO website: https://www.bio-rad.com


Get Full Access to All Reports with DRIPCalc PRO

Monthly
$35/mo
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial
Yearly - 20% OFF
$336/yr
7-days Free Trial
YMTracker & Earnings / Dividends / Estimate Reports for 1000s of Stocks
YMTracker
Visual Stock Research
Stock Comparison Tools
Dividend Stocks & ETFs
Revenue & EPS Estimates
Custom Dividend Reports
Start Free Trial